ohdsi-questions
Differences
This shows you the differences between two versions of the page.
| Both sides previous revision Previous revision | Next revision Both sides next revision | ||
|
ohdsi-questions [2018/04/13 23:48] rohit |
ohdsi-questions [2018/04/14 00:00] rohit |
||
|---|---|---|---|
| Line 49: | Line 49: | ||
| -Outcome - All-cause mortality as the primary outcome and asthma-related mortality as a secondary outcome. | -Outcome - All-cause mortality as the primary outcome and asthma-related mortality as a secondary outcome. | ||
| -Risk Window - 1st day of treatment exposure to end of the study. | -Risk Window - 1st day of treatment exposure to end of the study. | ||
| + | |||
| ===Question - 8=== | ===Question - 8=== | ||
| + | (Not sure what C/D stand for, I’ve asked this on the forum and will update once get a reply). | ||
| + | To compare the risk of asthma exacerbations between patients with Chronic Obstructive Pulmonary Disease (COPD) C/D and inhaled corticosteroids withdrawal versus patients with COPD C/D who have never used ICS. | ||
| + | -Treatment Cohort - Patients with COPD and inhaled corticosteroids withdrawal. | ||
| + | -Comparator Cohort - Patients with COPS not exposed to inhaled corticosteroids. | ||
| + | -Outcome - Asthma Exacerbations. | ||
| + | -Risk Window - 1 day after last exposure start to 180 days after the exposure end. | ||
| + | |||
| + | |||
| + | ===Question - 9=== | ||
| To compare the risk of serious cardiovascular events (sudden cardiac death, acute myocardial infarction, and stroke) between the new users of triptans versus patients who used triptans for one year (short-term) and more than one year (long-term). | To compare the risk of serious cardiovascular events (sudden cardiac death, acute myocardial infarction, and stroke) between the new users of triptans versus patients who used triptans for one year (short-term) and more than one year (long-term). | ||
| -Treatment Cohort - New users treated with triptans. | -Treatment Cohort - New users treated with triptans. | ||
| Line 57: | Line 67: | ||
| -Risk Window - 1 day after treatment exposure starts to 0 days after treatment exposure ends. | -Risk Window - 1 day after treatment exposure starts to 0 days after treatment exposure ends. | ||
| - | ===Question - 9=== | + | ===Question - 10=== |
| To compare the risk of osteoporosis or fracture increase in postmenopausal hypothyroid patients using high strength levothyroxine versus patients using low strength levothyroxine. | To compare the risk of osteoporosis or fracture increase in postmenopausal hypothyroid patients using high strength levothyroxine versus patients using low strength levothyroxine. | ||
| -Treatment Cohort - On treatment postmenopausal (age >=50 years) patients with hypothyroidism exposed to high strength of levothyroxine (>=0.044 mg/ | -Treatment Cohort - On treatment postmenopausal (age >=50 years) patients with hypothyroidism exposed to high strength of levothyroxine (>=0.044 mg/ | ||
| Line 64: | Line 74: | ||
| -Risk Window: From the first day of treatment with high or low strength levothyroxine until the end of cohort study, end of follow-up or death. | -Risk Window: From the first day of treatment with high or low strength levothyroxine until the end of cohort study, end of follow-up or death. | ||
| - | ===Question - 10=== | + | ===Question - 11=== |
| To compare the risk of chronic kidney disease (CKD) among patients exposed to proton pump inhibitors versus patients not exposed to proton pump inhibitors. | To compare the risk of chronic kidney disease (CKD) among patients exposed to proton pump inhibitors versus patients not exposed to proton pump inhibitors. | ||
| -Treatment Cohort - Patients with chronic exposure to proton pump inhibitors, age >= 18 years heaving no evidence of chronic kidney disease (eGFR < 60ml/min). | -Treatment Cohort - Patients with chronic exposure to proton pump inhibitors, age >= 18 years heaving no evidence of chronic kidney disease (eGFR < 60ml/min). | ||
| Line 70: | Line 80: | ||
| -Outcome - Incidence of chronic kidney disease. | -Outcome - Incidence of chronic kidney disease. | ||
| - | ===Question - 11=== | + | ===Question - 12=== |
| To compare the risk of Atherosclerotic Cardiovascular Disease (ACD) between patients with a diagnosis of hyperlipidemia (HLD) on statins and elevated triglycerides treated with fibrates versus patients with a diagnosis of HLD on statins and elevated triglycerides not treated with fibrates. | To compare the risk of Atherosclerotic Cardiovascular Disease (ACD) between patients with a diagnosis of hyperlipidemia (HLD) on statins and elevated triglycerides treated with fibrates versus patients with a diagnosis of HLD on statins and elevated triglycerides not treated with fibrates. | ||
| -Treatment Cohort - Patients with a diagnosis of HLD on statins and elevated triglycerides treated with fibrates. | -Treatment Cohort - Patients with a diagnosis of HLD on statins and elevated triglycerides treated with fibrates. | ||
| Line 77: | Line 87: | ||
| -Risk Window - 1 day after exposure start to 0 days after exposure ends. | -Risk Window - 1 day after exposure start to 0 days after exposure ends. | ||
| - | ===Question - 12=== | + | ===Question - 13=== |
| To compare the risk of Atherosclerotic Cardiovascular Disease (ACD) between patients with a diagnosis of hyperlipidemia (HLD) on statins with ideal cholesterol versus patients with a diagnosis of HLD on statins with elevated cholesterol. | To compare the risk of Atherosclerotic Cardiovascular Disease (ACD) between patients with a diagnosis of hyperlipidemia (HLD) on statins with ideal cholesterol versus patients with a diagnosis of HLD on statins with elevated cholesterol. | ||
| -Treatment Cohort - Patients with the diagnosis of HLD treated with statins and have ideal cholesterol level. | -Treatment Cohort - Patients with the diagnosis of HLD treated with statins and have ideal cholesterol level. | ||
ohdsi-questions.txt · Last modified: 2018/06/04 20:14 by nigam
Page Tools
